Clinical Trials

Confirmatory Phase III Clinical Study

DIA-AID 2 (DiaPep277^® - Arresting Immune Diabetes)

DIA-AID 2 is a confirmatory phase III study which is ongoing. This study is a global clinical trial which is being conducted at more than 120 clinical study sites. Patient recruitment has been completed and the study is expected to be completed at the end of 2014.

Eligible patients for the study are between 20 to 45 years of age and within 6 months of diagnosis of type 1 diabetes. Furthermore, the study requires a residual beta cell function when fasting of C-peptide ≥ 0.2nmol/L.

Patients are randomized to 1.0 mg DiaPep277^® or placebo with primary endpoint beta cell preservation of function.

Study Steering Committee

Prof. Itamar Raz
Hadassah Medical Center
Jerusalem, Israel
Prof. Paolo Pozzilli
Università Campus Bio-Medico di Roma
Rome, Italy
Prof. Thomas Linn
Universitätsklinikum Giessen
Giessen, Germany
Prof. Francois Bonnici
New Groote Schuur Hospital
Capetown, South Africa
Prof. Philip Raskin
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
USA